Acesso livre
Acesso livre

Infectologia

Vacina CoronaVac: os resultados são conflitantes, mas o mundo não pode ignorar sua utilidade.

27 Jul, 2021 | 10:23h

CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness – The Conversation

Conteúdos Relacionados:

RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.

Prospective national cohort in Chile showed CoronaVac effectiveness was 65.9% for symptomatic Covid-19, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

Perspective | Are Chinese COVID vaccines underperforming? a dearth of real-life studies leaves unanswered questions.

WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.

Brazilian town experiment shows mass vaccination can wipe out COVID-19.

WHO validates Sinovac-CoronaVac COVID-19 vaccine for emergency use and issues interim policy recommendations.

[Press release – not published yet] The city of Serrana in Brazil has seen a 95% drop in Covid-19 deaths after almost all adults were vaccinated with Chinese CoronaVac – The findings suggest the pandemic can be controlled after 75% of people are fully vaccinated.

[Not published yet] Observational study in Uruguay found CoronaVac reduced mortality by 97 percent – “In people who had received two doses, it reduced infection with the coronavirus by 57 percent and intensive care admissions by 95 percent”.

Diretriz NICE | Infecção por Clostridioides difficile infection: prescrição de antibióticos.

27 Jul, 2021 | 10:22h

Clostridioides difficile infection: antimicrobial prescribing – National Institute for Health and Care Excellence

Infográfico: Clostridioides difficile infection: antimicrobial prescribing

Conteúdos Relacionados:

IDSA 2021 focused update guidelines on the management of Clostridioides difficile infection in adults.

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.

Prevention of Clostridioides difficile in hospitals: A position paper of the International Society for Infectious Diseases

Review | My Treatment Approach to Clostridioides difficile Infection.

Estudo randomizado por clusters | Eficácia de uma intervenção personalizada para reduzir o uso de antibióticos no tratamento de infecções do trato urinário em residentes de casas de repouso.

27 Jul, 2021 | 10:14h

Effectiveness of a tailored intervention to reduce antibiotics for urinary tract infections in nursing home residents: a cluster, randomised controlled trial – The Lancet Infectious Diseases (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

[Preprint] RCT: Em pacientes com COVID-19 e hipóxia grave, a dexametasona 12 mg NÃO resultou em melhora estatisticamente significativa nos desfechos em comparação com a dexametasona 6 mg – “A mortalidade em 28 dias foi de 27,1% e 32,3% em pacientes atribuídos a 12 mg e 6 mg, respectivamente (risco relativo ajustado 0,86, 99% IC, 0,68-1,08).”

26 Jul, 2021 | 10:24h

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial – medRxiv

Estudo de coorte mostrou que 1 em cada 2 pacientes hospitalizados com COVID-19 desenvolve complicação.

26 Jul, 2021 | 10:23h

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study – The Lancet

Comentários:

Landmark study finds one in two hospitalised COVID-19 patients develop a complication – National Institute for Health Research

In-hospital complications associated with COVID-19 – The Lancet

CV Complications Common in Hospitalized COVID-19 Patients – TCTMD

Almost Half of Patients Admitted With COVID-19 Have Complications – HealthDay

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo de coorte | Manifestações neurológicas da infecção por SARS-CoV-2 em crianças e adolescentes hospitalizados no Reino Unido – “Em torno de 1 em cada 20 crianças hospitalizadas com COVID-19 desenvolveu complicações neurológicas associadas à infecção viral.”

26 Jul, 2021 | 10:21h

Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study – The Lancet Child & Adolescent Health

Comentários:

Neuroinflammation triggered by SARS-CoV-2 infection: syndromes and therapies – The Lancet Child & Adolescent Health

New UK study reveals extent of brain complications in children hospitalized with COVID-19 – University of Liverpool

 

Comentário no Twitter

 

M-A | Pacientes psiquiátricos têm risco aumentado de hospitalização e morte por COVID-19.

26 Jul, 2021 | 10:20h

Comunicado de imprensa: Psychiatric patients at increased risk of COVID-19 hospitalization and mortality – European College of Neuropsychopharmacology

Artigo original: Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis – The Lancet Psychiatry

Estudo mostra que o teste de antígeno de fluxo lateral pode detectar, de modo rápido e acurado, a COVID-19 inicial em pacientes com sintomas gripais e pode ser uma alternativa plausível ao RT-PCR.

26 Jul, 2021 | 10:19h

Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2) – EClinicalMedicine

Comunicado de imprensa: Lateral flow tests are 95% effective at detecting Covid-19 when used at the onset of symptoms – University of Oxford

Relacionado:

Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.

Rapid point-of-care tests for diagnosing COVID-19 infection: the latest Cochrane evidence

 

Comentário no Twitter (fio – clique para saber mais)

 

Entre receptores de transplante de rim que não tiveram resposta imune adequada a 2 doses, uma terceira dose de vacina mRNA induziu resposta sorológica em 49% dos pacientes.

26 Jul, 2021 | 10:18h

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses – JAMA

Comentário: Case Mounts for COVID Vaccine Boosters in Kidney Transplant Recipients – MedPage Today (necessário cadastro gratuito)

Relacionado:

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

[Preprint] 3rd AstraZeneca shot gives strong immunity.

 

Comentário no Twitter

 

Relato de caso | Síndrome inflamatória multissistêmica similar a doença de Kawasaki associada a infecção por SARS-CoV-2 em adulto.

26 Jul, 2021 | 10:16h

Kawasaki-like multisystem inflammatory syndrome associated with SARS-CoV-2 infection in an adult – BMJ Case Reports

Relacionado:

Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.

Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection

Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection

Case Reports: 2 Adults with Kawasaki-like Multisystem Inflammatory Syndrome Associated with COVID-19

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.